News
Alpha1H shows benefit in non-muscle invasive bladder cancer, shrinking tumors and boosting the immune system with manageable ...
Akeso enrolls first patient in pivotal phase III trial of cadonilimab for perioperative treatment of resectable gastric cancer: Hong Kong Friday, August 22, 2025, 18:00 Hrs [IST] ...
Levelle Nutrition Co-founder and CEO Linda Alvarez discusses the timely launch of Cycle Syncing Protein and its broader ...
As regulators push to phase out animal testing, Charles River’s Steve Bulera notes that widespread implementation of ...
4h
Zacks Investment Research on MSNAbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth
AbbVie ABBV holds a dominant position in the immunology market, which is being aided by strong sales of its two new ...
UCLA’s cancer research has been deeply impactful, with millions of people receiving drugs and therapies developed in Bruin ...
Mumbai: Parexel, a global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to ...
18h
Stockhead on MSNTryptamine secures landmark EEG biomarker deal to advance precision psychiatry
Tryptamine Therapeutics has struck an exclusive deal with world-leading psychedelic researchers Professor Robin ...
USD is seeking more than $293.5 million in funding for various projects over the years to come, for everything from ...
Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...
In response to a proposal submitted by Ravenbhel Healthcare of the fixed dose combination (FDC) pulmonary drug Bilastine 10 ...
5h
Zacks Investment Research on MSNIs Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?
Eli Lilly and Company LLY is a key player in the diabetes and obesity drug market, mainly due to the significant popularity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results